Masatoshi Nozaki

Dr. Masatoshi Nozaki

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2022 in The Journal of Pediatrics
Verified
Journal Article
Open access
HSHisato Suzuki
Hisato Suzuki
MNMasatoshi Nozaki
Masatoshi Nozaki
HYHiroshi Yoshihashi
Hiroshi Yoshihashi
KIKazuo Imagawa
Kazuo Imagawa
DKDaigo Kajikawa
Daigo Kajikawa
TTToshiki Takenouchi
Toshiki Takenouchi
To delineate the diagnostic efficacy of medical exome, whole exome, and whole genome sequencing according to primary symptoms, the contribution of small copy number variations, and the impact of molecular diagnosis on clinical management. This was a prospective study of 17 tertiary care centers in Japan, conducted between April 2019 and March 2021. Critically ill neonates and infants less than 6 months of age were recruited in neonatal intensive care units and in outpatient clinics. The patients underwent medical exome, whole exome, or whole genome sequencing as the first tier of testing. Patients with negative results after medical exome or whole exome sequencing subsequently underwent whole genome sequencing. The impact of molecular diagnosis on clinical management was evaluated through contacting primary care physicians. Of the 85 patients, 41 (48%) had positive results. Based on the primary symptoms, patients with metabolic phenotypes had the highest diagnostic yield (67%, 4/6 patients), followed by renal (60%, 3/5 patients), and neurologic phenotypes (58%, 14/24 patients). Among them, 4 patients had pathogenic small copy number variations identified using whole genome sequencing. In the 41 patients with a molecular diagnosis, 20 (49%) had changes in clinical management. Genome analysis for critically ill neonates and infants had a high diagnostic yield for metabolic, renal, and neurologic phenotypes. Small copy number variations detected using whole genome sequencing contributed to the overall molecular diagnosis in 5% of all the patients. The resulting molecular diagnoses had a significant impact on clinical management.

3 August 2006 in Toxicon
Verified
Journal Article
Closed access
TCTakahito Chijiwa
Takahito Chijiwa
ETEmi Tokunaga
Emi Tokunaga
RIRyo Ikeda
Ryo Ikeda
KTKoki Terada
Koki Terada
Tomohisa OgawaTomohisa Ogawa
Tomohisa Ogawa
MOMotonori Ohno
Motonori Ohno

25 March 2023 in Brain and Development
Verified
Journal Article
Closed access
TKTomokazu Kimizu
Tomokazu Kimizu
SIShinobu Ida
Shinobu Ida
KOKeisuke Oki
Keisuke Oki
MSMorimasa Shima
Morimasa Shima
SNShizuka Nishimoto
Shizuka Nishimoto
YSYasuhiro Suzuki
Yasuhiro Suzuki

28 February 2024 in Genes
Verified
Journal Article
Open access
PDF file
TKTomokazu Kimizu
Tomokazu Kimizu
MNMasatoshi Nozaki
Masatoshi Nozaki
YOYousuke Okada
Yousuke Okada
ASAkihisa Sawada
Akihisa Sawada
MMMisaki Morisaki
Misaki Morisaki
SIShinobu Ida
Shinobu Ida
In newborn screening (NBS), it is important to consider the availability of multiplex assays or other tests that can be integrated into existing systems when attempting to implement NBS for new target diseases. Recent developments in innovative testing technology have made it possible to simultaneously screen for severe primary immunodeficiency (PID) and spinal muscular atrophy (SMA) using quantitative real-time polymerase chain reaction (qPCR) assays. We describe our experience of optional NBS for severe PID and SMA in Osaka, Japan. A multiplex TaqMan qPCR assay was used for the optional NBS program. The assay was able to quantify the levels of T-cell receptor excision circles and kappa-deleting recombination excision circles, which is useful for severe combined immunodeficiency and B-cell deficiency screening, and can simultaneously detect the homozygous deletion of SMN1 exon 7, which is useful for NBS for SMA. In total, 105,419 newborns were eligible for the optional NBS program between 1 August 2020 and 31 August 2023. A case each of X-linked agammaglobulinemia and SMA were diagnosed through the optional NBS and treated at early stages (before symptoms appeared). Our results show how multiplex PCR-based NBS can benefit large-scale NBS implementation projects for new target diseases.

26 May 2020 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
MHMasashi Hotta
Masashi Hotta
KHKatsuya Hirata
Katsuya Hirata
MNMasatoshi Nozaki
Masatoshi Nozaki
NMNarutaka Mochizuki
Narutaka Mochizuki
SHShinya Hirano
Shinya Hirano
KWKazuko Wada
Kazuko Wada

18 January 2023 in IJID Regions
Verified
Journal Article
Open access
SMShinsuke Mizuno
Shinsuke Mizuno
EOEiki Ogawa
Eiki Ogawa
MNMasatoshi Nozaki
Masatoshi Nozaki
YCYoshiaki Cho
Yoshiaki Cho
MKMasashi Kasai
Masashi Kasai
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant emergence preceded a wave of pediatric coronavirus disease 2019 (COVID-19) cases, putting considerable strain on hospitals across Japan. Our study evaluated the pediatric disease burden of COVID-19 in pediatric hospitals. This retrospective study evaluated all pediatric patients (defined as aged < 21 years) hospitalized with SARS-CoV-2 infection, or as close contacts, at four children's hospitals, between January 1 and May 31, 2022. Clinical characteristics, reasons for admission, and outcome data were analyzed. In total, 492 patients (median age 3.0 years; male 58.7%) were included over the study period. Of these, 232 (47.2%) patients had at least one underlying disease. Asymptomatic and mild diseases were common during the study period (n = 451, 91.7%). Social reasons for hospitalization (including a lack of family support at home) accounted for 36.8% (n = 181) of inpatients. The median length of stay was 4.0 days. Fever was the most common symptom (n = 273, 55.5%), followed by upper respiratory (n = 77, 15.7%) and neurological (n = 60, 12.2%) symptoms. Overall, 34 (6.9%) children required invasive mechanical ventilation, 51 (10.4%) were admitted to the pediatric intensive care unit, and two (0.4%) died. COVID-19 vaccination rate was low (n =14/200, 7.0%). The disease burden during the Omicron-predominant period was attributable to asymptomatic and mild infections, and some patients were hospitalized for social reasons. To maintain a medical care system for critically ill patients, each medical facility must play a role according to its function.